Welcome Our work Our team
Welcome How we do it? Our team
Welcome Our work Our way Our team
Insight that inspires action
 
 

Basis Health is a global strategic insights consultancy, specializing in the life sciences industry, we operate at the intersection of strategy and execution

We partner with our clients to to ensure our approach is designed to effectively address your strategic support and output needs

 
 
 
 
 
 

Where do we need to go?

What is the best path to get there?

How do we navigate this path?

How does our route need to change?

 
 

This enables us to provide true partnership to our clients at every step, and deliver the right insights to drive business impact

 

We are Business 1st, Methodology 2nd

We deliver the Strategic ‘So-What’

Highly Customised, Data Agnostic Approach

We provide Proactive Partnership

 
 
 
 

Basis provides bespoke strategic advice for Pharma, Biotechs and Financiers to optimise the commercial development of early-stage assets

 

Product lifecycle Engagement types

 
 
 

TPP development & testing

Portfolio/ Pipeline Strategy & Indication Finding

Commercial Evaluation of Pipeline Assets

Business Development Support

Commercial Forecasting

Asset & Investment Identification Support

Competitive Intelligence

Market Access Support

 
 
 
 
 

Commercial planning early in the pipeline is critical to improving a product’s probability of success

 

Early commercial planning focuses on assessing and predicting how disease landscapes and standards of care will evolve in order to effectively position future pipeline assets and enable commercial success. It should be intrinsically linked to clinical and market access strategy

Goals:

Profiling the target market, scoping the unmet need to ensure the asset is addressing the need throughout pipeline development

Alignment with key internal stakeholders on the target profile and shaping its value

Ensuring asset differentiation, patient centricity and value is generated as part of the clinical program

Challenges:

Forecasting how the market will evolve in an increasingly and rapidly evolving competitive environment - Key to ensure the asset remains differentiated

Changes in healthcare policy and barriers to market access -importance of ensuring the value of the asset to key stakeholders is clearly defined

 
 
Asset 30early access.png
 
 
 

Commercial evaluation either to support BD&L or commercial planning requires a full assessment of the future landscape; using robust, scientific led approaches

 
 

Opportunity mapping

Opportunity mapping

 

Sizing the target patient population

Considerations:

Which indication should be pursued, what are the dynamics?

What is the epidemiology of the target patient population?

How will that impact clinical trial strategy?

How concentrated is the target physician community?

Determine price and value

Considerations:

What are the market access and reimbursement challenges?

How do you generate value through the clinical trial design?

Identifying areas of patient unmet need

Considerations:

Where are patients being underserved now and in the future?

How does the condition impact patient’s QoL?

How can a new product address this unmet need?

Evaluating current and future pipeline competition (drug and non-drug)

Considerations:

What is the breadth and depth of the future pipeline?

Which MoAs, devices and technology are in development?

What is the probability of success of these assets?

What are the potential launch dates and patent expiries?

 
 
 
 

Basis has a broad framework approach to asset evaluation, however each project would incorporate a customized set of services that are specific to your needs.

 

Approach

 

Secondary sources & RWE analysis for market landscaping

Qualitative KOL interviews for initial opportunity assessment

Semi-Quantitative HCP research to determine peak shares

Payor research to assess achievable price range

 

Forecasts to determine peak revenues

Forecasts to determine peak revenues

Impact

 

Clear commercial direction on where the opportunity lies for the asset with strategic insight into positioning and competitive intensity

Strategic focus on the value of the asset and achievable price range to help define market access strategy

Forecasts that can be used for valuations and investor funding routed in clinical-outcome based scenarios

Stakeholder engagement with input into both clinical and commercial strategy

 
 
Asset 30early access.png
 
 
 

The best insights need integration – Basis designs the best solution to address your commercial needs, agnostic of methodology & data source, with thorough consolidation of evidence-led secondary research and primary research

 
 
 

Insight Generation

Strategic Direction

 

Sources & Technologies

 

Behavioural Science Framework

Real-World Data

Secondary Data Subscriptions

Artificial Intelligence

 
 
 

Rebecca Roberts

Associate Partner, Early Asset Commercialisation Practice Lead
roberts@basisresearch.com
+44 (0)20 7255 2000

 
red.png